See more : Caire (MLAAE.PA) Income Statement Analysis – Financial Results
Complete financial analysis of Avalon GloboCare Corp. (AVCO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Avalon GloboCare Corp., a leading company in the Real Estate – Services industry within the Real Estate sector.
- Bosideng International Holdings Limited (3998.HK) Income Statement Analysis – Financial Results
- Easy Technologies Inc. (EMYSF) Income Statement Analysis – Financial Results
- Autris (AUTR) Income Statement Analysis – Financial Results
- Thomas Cook (India) Limited (THOMASCOOK.NS) Income Statement Analysis – Financial Results
- Forbion European Acquisition Corp. (FRBN) Income Statement Analysis – Financial Results
Avalon GloboCare Corp. (AVCO)
About Avalon GloboCare Corp.
Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and the People's Republic of China. The company offers medical related consulting services, including research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services in the areas of immunotherapy and second opinion/referral services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing RNA-based FASH-CARTM cell therapy platform. In addition, the company develops avalon clinical-grade tissue-specific exosome (ACTEX); offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Further, it has strategic partnership with the University of Natural Resources and Life Sciences in Vienna and Austria to develop an S-layer vaccine that could be administered by an intranasal or oral route against SARS-CoV-2 and coronavirus that causes COVID-19 disease; and develops Avalon Cell and Avalon Rehab, as well as promotes standardization related to exosome industry. The company is headquartered in Freehold, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.26M | 1.20M | 1.39M | 1.38M | 1.55M | 1.56M | 1.08M | 616.45K | 0.00 |
| Cost of Revenue | 1.02M | 929.44K | 976.45K | 987.56K | 1.21M | 1.17M | 829.79K | 73.07K | 0.00 |
| Gross Profit | 238.19K | 272.73K | 414.52K | 390.20K | 339.91K | 388.01K | 247.76K | 543.38K | 0.00 |
| Gross Profit Ratio | 18.97% | 22.69% | 29.80% | 28.32% | 21.98% | 24.84% | 22.99% | 88.15% | 0.00% |
| Research & Development | 109.62K | 731.33K | 1.03M | 883.86K | 1.78M | 39.06K | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.64M | 5.66M | 8.22M | 11.96M | 16.93M | 7.68M | 2.79M | 459.55K | 31.01K |
| Selling & Marketing | 1.67M | 1.33M | 328.57K | 294.35K | 685.06K | 335.90K | 15.25K | 6.89K | 0.00 |
| SG&A | 7.31M | 6.98M | 8.22M | 11.96M | 16.93M | 8.02M | 2.80M | 466.45K | 31.01K |
| Other Expenses | 8.57M | -120.51K | 4.27K | -4.98K | 3.26K | -11.35K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.99M | 7.72M | 9.25M | 12.84M | 18.71M | 7.96M | 2.78M | 466.45K | 31.01K |
| Cost & Expenses | 17.01M | 8.65M | 10.22M | 13.83M | 19.91M | 9.13M | 3.61M | 539.51K | 31.01K |
| Interest Income | 0.00 | 3.58M | 200.48K | 168.76K | 82.91K | 4.31K | 1.37K | 575.00 | 0.00 |
| Interest Expense | 1.35M | 3.58M | 200.48K | 168.76K | 82.91K | 314.65K | 138.11K | 0.00 | 0.00 |
| Depreciation & Amortization | 329.95K | 466.28K | 438.78K | 378.48K | 506.74K | 522.84K | 181.64K | 26.00 | 175.51K |
| EBITDA | -15.03M | -7.89M | -8.39M | -12.08M | -16.90M | -7.16M | -3.73M | 77.53K | -31.01K |
| EBITDA Ratio | -1,196.61% | -593.84% | -607.58% | -880.57% | -1,192.42% | -454.97% | -218.21% | 12.48% | 0.00% |
| Operating Income | -15.75M | -7.44M | -8.83M | -12.45M | -18.37M | -7.63M | -3.88M | 76.93K | -31.01K |
| Operating Income Ratio | -1,254.59% | -619.12% | -635.08% | -903.93% | -1,187.81% | -488.46% | -359.88% | 12.48% | 0.00% |
| Total Other Income/Expenses | -953.33K | -3.14M | -256.67K | -225.42K | 1.31M | -421.16K | -171.78K | 575.00 | 0.00 |
| Income Before Tax | -16.71M | -11.93M | -9.09M | -12.68M | -18.07M | -8.05M | -4.05M | 77.51K | -31.01K |
| Income Before Tax Ratio | -1,330.51% | -992.44% | -653.54% | -920.29% | -1,168.60% | -515.42% | -375.82% | 12.57% | 0.00% |
| Income Tax Expense | 0.00 | 749.25K | 144.29K | 112.11K | 30.39K | -278.17K | -585.36K | 21.93K | -175.50K |
| Net Income | -16.71M | -12.68M | -9.23M | -12.79M | -18.10M | -7.77M | -3.46M | 55.58K | -31.01K |
| Net Income Ratio | -1,330.51% | -1,054.77% | -663.91% | -928.43% | -1,170.57% | -497.61% | -321.50% | 9.02% | 0.00% |
| EPS | -1.59 | -1.36 | -1.09 | -1.61 | -2.41 | -1.08 | -0.53 | 0.01 | -0.18 |
| EPS Diluted | -1.59 | -1.36 | -1.09 | -1.61 | -2.41 | -1.08 | -0.53 | 0.01 | -0.18 |
| Weighted Avg Shares Out | 10.53M | 9.33M | 8.49M | 7.95M | 7.51M | 7.20M | 6.50M | 5.11M | 175.00K |
| Weighted Avg Shares Out (Dil) | 10.53M | 9.33M | 8.49M | 7.95M | 7.51M | 7.20M | 6.50M | 5.11M | 175.00K |
UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCare
UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCare
Avalon GloboCare, UPMC Hillman and University of Pittsburgh to develop new cancer immunotherapy
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Avalon GloboCare Corp. - AVCO
Avalon GloboCare says its planned acquisition target SenlangBio starts first-in-human clinical trial for recurrent brain cancer
Avalon GloboCare says SenlangBio will enhance its capabilities in cell and gene therapy
Avalon GloboCare CEO Provides Letter to Update Shareholders About Acquisition of SenlangBio
Avalon Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Avalon GloboCare Corp. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – AVCO
Avalon Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Avalon GloboCare Corp. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – AVCO
Avalon GloboCare Adds Cell Therapy-Based Candidates For Cancer With SenlangBio Acquisition: Highlights
Source: https://incomestatements.info
Category: Stock Reports